PHVS
Pharvaris N.V.
25.93
USD
This page is just a preview of the data found in TrendSpider’s full version
Pharvaris N.V. stock is up 54.81% since 30 days ago. The next earnings date is Apr 3, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 67% of analysts rate it a buy.
Pharvaris N.V. focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE) The company was incorporated in 2015 and is based in Leiden, the Netherlands.
